165 completed. 165 Phase 2, 19 Phase 1, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 165 | Completed 165 |
| Phase 1 | 19 | Completed 19 |
| Phase 3 | 9 | Completed 9 |
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures NPT 2042, Placebo - Epilepsy, Generalized, Epilepsy, Absence | Phase 2 | Completed | NeuroPro Therapeutics, Inc. | 14 | 2025-03-11 | 2026-09-28 |
| Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy RAP-219 - Focal Onset Seizures | Phase 2 | Completed | Rapport Therapeutics Inc. | 30 | 2024-10-10 | 2026-02-05 |
| Prospective Pilot Trial to Address Feasibility and Safety of Oral Zinc in GNAO1 Associated Disorders Zinc Acetate Dihydrate - GNAO1, Dystonia | Phase 2 | Completed | Children's University Hospital Cologne, Germany | 13 | 2024-08-02 | 2026-02-03 |
| Safety and Efficacy of tPBM for Epileptiform Activity in Autism noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - Autism Spectrum Disorder, EEG With Periodic Abnormalities | Phase 2 | Completed | Richard Frye | 6 | 2024-07-01 | 2026-09-22 |
| Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD). Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 16 | 2023-09-22 | 2024-11-29 |
| OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION) OMT-28 - Primary Mitochondrial Disease | Phase 2 | Completed | Omeicos Therapeutics GmbH | 28 | 2023-05-22 | 2026-01-22 |
| Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy LP352, bexicaserin - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 2 | Completed | Longboard Pharmaceuticals | 41 | 2022-11-08 | 2025-12-03 |
| Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy Lactobacillus-Based Capsule - Drug Resistant Epilepsy | Phase 2 | Completed | Tanta University | 60 | 2022-09-25 | 2025-07-01 |
| the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy N-acetyl cysteine, Placebo, NAc - Drug Resistant Epilepsy | Phase 2 | Completed | Tanta University | 90 | 2022-09-15 | 2025-07-01 |
| Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy Oral 2-Deoxy-D-Glucose (2DG) - Epilepsy; Seizure | Phase 2 | Completed | University of Virginia | 9 | 2022-09-02 | 2026-06-09 |
| The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy Ketamine Hydrochloride - Drug Resistant Epilepsy, Medically Refractory Epilepsy | Phase 2 | Completed | Madeline Fields | 12 | 2022-08-26 | 2026-09-11 |
| Helicobacter Pylori Eradication Therapy for Epileptic Children Triple therapy for H. pylori infection - Epilepsy, Generalized, Helicobacter Pylori Infection | Phase 2 / Phase 3 | Completed | Sohag University | 126 | 2022-04-20 | 2024-01-29 |
| Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies LP352, Placebo - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 1 / Phase 2 | Completed | Longboard Pharmaceuticals | 52 | 2022-03-03 | 2024-11-08 |
| Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study Clioquinol - Epilepsy Intractable | Phase 2 | Completed | KU Leuven | 10 | 2022-03-01 | 2026-10-20 |
| A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures NBI-921352, Placebo - Focal Onset Seizure, Focal Onset Epilepsy | Phase 2 | Completed | Neurocrine Biosciences | 101 | 2021-11-08 | 2024-09-26 |
| Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy Diazepam Nasal Spray [Valtoco] - Epilepsy | Phase 1 / Phase 2 | Completed | Neurelis, Inc. | 36 | 2021-11-08 | 2026-10-20 |
| Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants TAVT-18 (sirolimus) - Tuberous Sclerosis Complex, Epilepsy | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 5 | 2020-09-08 | 2024-05-16 |
| An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome STK-001 - Single Ascending Doses, STK-001 - Multiple Ascending Doses - Dravet Syndrome | Phase 1 / Phase 2 | Completed | Stoke Therapeutics, Inc | 62 | 2020-06-29 | 2025-05-18 |
| A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures Placebo, CVL-865 - Seizures | Phase 2 | Completed | AbbVie | 154 | 2020-01-27 | 2025-05-30 |
| Measuring Blood Flow in the Brain After Epileptic Activity Paracetamol, Nimotop - Epilepsy, Depression | Phase 2 | Completed | Rijnstate Hospital | 34 | 2019-12-05 | 2023-11-18 |
Showing 20 of 165. Sign in to see all of them.
Seizures (54) · Epilepsies, Partial (24) · Drug Resistant Epilepsy (14) · Brain Diseases (7) · Epilepsies, Myoclonic (7) · Epilepsy, Reflex (6) · Tuberous Sclerosis (6) · Migraine Disorders (5) · CDKL5 deficiency disorder (4) · Lennox Gastaut Syndrome (4) · Spasms, Infantile (4) · Autistic Disorder (3) · Central Nervous System Diseases (3) · Epilepsy, Generalized (3)
Nervous System Diseases (163) · Central Nervous System Diseases (162) · Brain Diseases (158) · Pathological Conditions, Signs and Symptoms (62) · Signs and Symptoms (61) · Neurologic Manifestations (59) · Epileptic Syndromes (15) · Epilepsy, Generalized (13) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Genetic Diseases, Inborn (11) · Neoplasms (8) · Neurodegenerative Diseases (8) · Congenital Abnormalities (7) · Heredodegenerative Disorders, Nervous System (7)
Levetiracetam (14) · perampanel (9) · Lacosamide (8) · Cannabidiol (6) · Topiramate (6) · brivaracetam (6) · ganaxolone (6) · eslicarbazepine acetate (5) · Cenobamate (3) · Clobazam (3) · Everolimus (3) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (3) · Sumatriptan (3) · 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)- (2) · Carbamazepine (2)
UCB Pharma (14) · Jazz Pharmaceuticals (9) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (7) · Marinus Pharmaceuticals (7) · SK Life Science, Inc. (6) · Bial - Portela C S.A. (5) · Children's Hospital Medical Center, Cincinnati (5) · Eisai Co., Ltd. (5) · UCB BIOSCIENCES, Inc. (5) · Eisai Inc. (4) · National Institute of Neurological Disorders and Stroke (NINDS) (4) · Aquestive Therapeutics (3) · UCB Biopharma S.P.R.L. (3) · All India Institute of Medical Sciences (2) · GlaxoSmithKline (2)
United States (100) · Germany (19) · Spain (19) · France (16) · Poland (16) · Hungary (14) · Australia (13) · Italy (13) · Belgium (12) · United Kingdom (12) · Mexico (11) · Netherlands (11) · Czechia (10) · India (7) · Japan (6)
Christopher M DeGiorgio, MD (2) · Dennis J Dlugos, MD (2) · Gary Slatko (2) · Gretchen L Birbeck, M.D. (2) · Jacqueline French, M.D. (2) · Orrin Devinsky, MD (2) · Satinder Aneja, MD (2) · Sheffali Gulati, MD (2)
PMID 35305920, PMID 37059702, PMID 28086164, PMID 31672143, PMID 31937513, PMID 35285519, PMID 16499758, PMID 17888078, PMID 18513353, PMID 18711110, PMID 19001248, PMID 19702752, PMID 20041945, PMID 20547106, PMID 20667792, PMID 21167786, PMID 21332573, PMID 21883097, PMID 21920781, PMID 22771222, PMID 22777131, PMID 22813235, PMID 22913800, PMID 23219031, PMID 23365066, PMID 23533164, PMID 23798472, PMID 23876024, PMID 24999157, PMID 25201887, PMID 25377429, PMID 25461210, PMID 25769377, PMID 25963722, PMID 26696953, PMID 26724782, PMID 26984901, PMID 27265725, PMID 27693237, PMID 28500900, PMID 29653338, PMID 29878341, PMID 30146701, PMID 30427550, PMID 30877186, PMID 30877622, PMID 31292226, PMID 31734103, PMID 31878820, PMID 32350749
2014 (10), 2017 (3), 2018 (3), 2004 (2), 2015 (2), 2016 (2), R01NS074409 (2), 2005 (1), 2019 (1), R01NS042698 (1), R01NS054805 (1), R01NS094257 (1), U54NS078059 (1)